About the MMRC
The first of its kind
The MMRC is the first collaborative research organization of its kind. It brings together academic and community cancer centers with industry, to advance innovative Phase 1 and Phase 2 clinical trials of today’s most promising drug candidates.
How it connects
MMRC Member Institutions are supported by an advanced infrastructure, including a cutting-edge tissue bank and IT systems that enable rapid, seamless collaboration.
Driven to achieve results
Driven by highly defined metrics that mandate accountability and strongly promote team science, the MMRC typically begins trials 60% faster and enrolls patients 10% faster than the industry standard.
The MMRC is aggressively investigating many molecularly targeted, immune, and novel agents.
We are also working on a Master Protocol approach – a unique and modern pivotal trial design that could dramatically accelerate the development of targeted therapies by addressing many of the challenges of traditional clinical trials. These include cost, patient participation and effective design. This unprecedented and unmatched clinical development platform is speeding, refining, and enhancing clinical trial enrollment, reducing the cost of drug development, and ultimately—by determining the best therapeutic fit for patients — improving treatment outcomes.
The MMRC brings together an extraordinary assembly of distinguished myeloma researchers and world-renowned academic institutions to speed translational and clinical developments in myeloma.LEARN MORE
This multidisciplinary team, with expertise in the fields of multiple myeloma research, clinical care, and executive leadership, provides both strategic direction and scientific oversight to the Consortium.LEARN MORE
Our world-renown team of experts driving the work of the MMRC.LEARN MORE